Kei Kishimoto, Ph.D.

Dr. Kishimoto is an accomplished immunologist and drug developer with over 30 years of experience in developing biologic, genetic, small molecule, carbohydrate-based, and nanoparticle therapies and vaccines for allergy, autoimmune diseases, and oncology. He was most recently Chief Scientific Officer of Selecta Biosciences, where he led discovery and development of a novel antigen-specific immune tolerance technology which was successfully validated in phase 3 clinical trials.  Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto held positions of increasing responsibility at Momenta Pharmaceuticals, Millennium Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto received his Ph.D. in Immunology from Harvard University and postdoctoral training at Stanford University, and has published numerous peer-reviewed articles in journals including Nature, Science, Cell and The New England Journal of Medicine. Dr. Kishimoto is currently an independent consultant.